Association Between Serum Uric Acid and the Risk of Gestational Diabetes Mellitus: A Multicenter Cohort Study

Why It Matters

Identifying elevated uric acid early enables targeted monitoring and preventive strategies, potentially reducing GDM‑related maternal and neonatal complications.

Key Takeaways

• Serum uric acid >240 μmol/L raises GDM risk by 47% after adjustment
• Levels ≥360 μmol/L more than double odds of developing GDM
• Mendelian randomization confirms a causal link between uric acid and GDM
• Early‑pregnancy uric acid testing is inexpensive and widely available
• Findings hold across age, BMI, and parity subgroups

Pulse Analysis

The recent multicenter cohort, encompassing over 44,000 singleton pregnancies, provides robust evidence that serum uric acid measured in the first trimester is a strong predictor of gestational diabetes mellitus. Using smooth‑curve fitting and threshold‑effect models, researchers identified a nonlinear risk curve with a pivotal inflection at 240 μmol/L. Women whose uric acid fell between 240 and 359 μmol/L faced a 47 % higher adjusted odds of GDM, while concentrations at or above 360 μmol/L more than doubled that risk. These associations persisted after controlling for age, BMI, family history, and metabolic markers, underscoring the biomarker’s independent predictive value.

Beyond observational data, the study leveraged two‑sample Mendelian randomization to probe causality. By integrating 228 independent genetic variants linked to uric acid from large European GWAS and GDM outcomes from the FinnGen cohort, the analysis revealed a statistically significant causal effect: each standard‑deviation increase in genetically predicted uric acid raised GDM risk by 12 %. Complementary MR methods (weighted median, MR‑Egger) corroborated the finding, while sensitivity tests ruled out horizontal pleiotropy. This genetic validation strengthens the biological plausibility that elevated uric acid contributes directly to insulin resistance and endothelial dysfunction during pregnancy.

Clinically, the implications are immediate. Uric acid testing is inexpensive, routinely performed, and can be incorporated into first‑trimester screening panels. Early identification of high‑risk women allows obstetric teams to intensify lifestyle counseling, monitor glucose more closely, and consider preventive interventions such as dietary modifications or, in the future, uric‑lowering agents. Further trials are needed to determine whether lowering uric acid can actually reduce GDM incidence, but the current evidence positions serum uric acid as a valuable tool for risk stratification in prenatal care.